WITHDRAWal of heart failure directed therapies in recovered Atrial Fibrillation mediated cardiomyopathy- investigating the impact on left ventricular ejection fraction: the WITHDRAW-AF study

Alfred Hospital0 个研究点目标入组 60 人开始时间: 2021年7月8日最近更新: 2024年9月2日

适应症

试验速览

暂无简介。

•Age>18 years
•- AF mediated cardiomyopathy
•Previous LVEF <40% in the setting of AF with recovery to >50% within 6 months after
•restoration of sinus rhythm (with anti-arrhythmic medications, electrical cardioversion,
•catheter ablation or any combination of these)
•- NYHA class I
•- Currently on pharmacological anti-heart failure therapy including at least 2 of:
•-ACE inhibitor or Angiotensin receptor antagonist
•-Diuretic (excluding MRA)
•-Cardiac specific beta blocker
•-Mineralocorticoid receptor antagonist
•-Entresto (Sacubitril/Valsartan)
•- No recurrence of AF with previous 6 months
•- No heart failure related admissions with last 6 months
•- Cardiac MRI demonstrating
•-LVEF >/=50%
•-The absence of ventricular late gadolinium enhancement
•-Indexed LVEDV less than 10% upper limit of normal
•- Able to consent
•- Willing to adhere to follow up requirements

•- Patients with unsuccessful rhythm control
•- Patients with known contributing cause of LV dysfunction including
•-Ischaemic cardiomyopathy
•-Valvular heart disease
•-Hypertrophic cardiomyopathy
•-Uncontrolled current/ongoing alcohol intake
•-Other cause of cardiomyopathy (eg thyroid disease)
•- Significant renal impairment (eGFR<30mL/min/1.73m2)
•- Contraindication to
•-cardiac MRI,
•-catheter ablation or
•-anti-coagulation
•- Any condition with expected survival < 2 years
•- Patients with a clear indication for ACE/ARB therapy for reasons other than heart failure where alternative agents are contra-indicated or inappropriate
•- Unable to provide informed consent

发起方

Alfred Hospital